Preclinical investigations have demonstrated that pharmacological modulation of KOR confers significant therapeutic benefits in a range of immune-related disorders, including atopic dermatitis, multiple sclerosis, and osteoarthritis. Here, OPRK1 is linked to multiple sclerosis.